Hematologist - blood malignancies, cell therapy and hematopoietic stem cell transplant, Head of hematology department at A.C.Camargo Cancer Center
São Paulo, Brasil
Joined December 2018
- Tweets138
- Following785
- Followers1.1K
- Likes373
Sundar Jagannath from @MountSinaiNYC brought a compelling perspective to Brazilian hematologists during a very emotional plenary session at the Brazilian Hematology Conference #HEMO2026: cure in myeloma as a tangible possibility. Sustained MRD negativity and advances in immunotherapy are giving this goal an increasingly concrete foundation. #CureMyeloma
4
166
Jayr Schmidt Filho retweeted
Guess what happens in the largest Hematology meeting of the Americas after ASH. Tip: Brazil+Rio.
#HEMO2026
Proud to share our latest publication in Neurological Sciences, highlighting the collaborative translational research efforts of our multidisciplinary team at A.C.Camargo Cancer Center.
In a patient with multiple myeloma, we combined SARS-CoV-2 detection in cerebrospinal fluid with advanced proteomic profiling, identifying 184 differentially expressed proteins and uncovering pathways associated with neuroinflammation, blood–brain barrier dysfunction, and potential neurodegenerative mechanisms.
@marjorierunning
🔗 doi.org/10.1007/s10072-026-0…
#MultipleMyeloma #TranslationalResearch #Neuroinflammation
Jayr Schmidt Filho retweeted
33 patients started teclistamab or talquetamab step-up dosing fully outpatient, with prophylactic tocilizumab.
CRS: 0.
Real-world poster from Mount Sinai at #IMS26, and the most useful part for community programs isn't the CRS rate. It's the eligibility list.
Jayr Schmidt Filho retweeted
ALT An illustrated list titled "Key Concepts" explaining terms related to anito-cel for multiple myeloma. It discusses Chimeric Antigen Receptor (CAR) T cells, Major Histocompatibility Complex (MHC), Monoclonal Antibodies, and T-cell Engagement. Each term includes a brief definition.
Jayr Schmidt Filho retweeted
Phase I results of Anito-cel and d-domain story published in NEJM! Exciting results and very delighted to be a part of this study @MedicalCollege @MCWCancerC2u8v
In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. Full study results: nej.md/4ArvK6r
Science behind the Study: Anito-cel for Multiple Myeloma nej.md/4hF5Gxj
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Phase 1 Study of Anito-cel, a D-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma." The graph shows progression-free survival among all patients who received anito-cel. The NEJM identity sits at the bottom.
Jayr Schmidt Filho retweeted
Real-World Brazilian Data Reveal Inequalities in MDS Care - Jayr Schmidt Filho (@jayrsf_ )
hemostasistoday.com/science/…
#HemostasisToday
Jayr Schmidt Filho retweeted
Advanced therapies like CAR T-cell treatment require coordination across clinicians, regulators, patient advocates, and health system stakeholders.
Our new paper in Frontiers in Hematology explores the challenges and opportunities for equitable CAR T-cell therapy access +
Jayr Schmidt Filho retweeted
Tailored infectious screening, including endemic pathogens, is critical in CAR-T candidates in endemic areas. Read in Blood Global Hematology: ow.ly/iWpH50Ysxle #CARTCell #BloodGlobal
Jayr Schmidt Filho retweeted
O Dr. Jayr Schmidt Filho (A.C.Camargo Cancer center), um dos palestrantes do V Multirregional SBTMO 2026, convida a todos para participarem do nosso Encontro de Prevenção e Tratamento de Recaídas pós TCTH, que ocorrerá na próxima semana, dia 13 de março! multirregionalsbtmo.com.br
Jayr Schmidt Filho retweeted
Great day sharing ideas, research, and debates on #myeloma with @bhemato and colleagues at MMSparks event in @merida #CureMyeloma #mmsm #MedEd #medtwitter #CART #bispecifics #MyelomaMexico #MyelomaFriends
Jayr Schmidt Filho retweeted
Newly diagnosed with MM? MASTER-2 addressed response adapted therapy with the perspective of finite treatment. Accruing fast! #mmsm
Great session at Brazilian Lymphoma Conference (BLC) 2025 from @abhhoficial: traditional debate on CART vs Bispecifics, with @GuiperiniMD, and moderated by Daniel Tabak and Belinda Simoes. The panel's overall opinion is that both therapies are complementary and not antagonistic.
5
290
Jayr Schmidt Filho retweeted
Necesitamos empujar el desarrollo y acceso de CAR-T en Latinoamérica.
Seguiremos empujando para avanzar.
#LEx25
Honored to participate in Lymphoma Experience (LEx), organized by @cytohance @iHematologo and @nico30f in Puerto Varas 🇨🇱
Pleasure to discuss the reality of CAR-T cell treatment in LATAM, sharing our experience through clinical cases presented by @ThaisFischer4 🩸🧬
Jayr Schmidt Filho retweeted
Had a great time debating @jayrsf_ and visiting with the great team at A.C Camargo Cancer Center earlier this week.
Jayr Schmidt Filho retweeted
Dr. @jayrsf_ hematologista, transplante de medula óssea e terapia celular, líder do centro de referência de neoplasia hematológicas do AC Camargo Câncer Center, tem uma mensagem sobre o Dia Mundial do Doador de Medula Óssea!
#globaldonordrive #thankyoudonor #WMDD23 #redome30anos – at Fortaleza, Brazil
Jayr Schmidt Filho retweeted
Amanhã, dia 03/08 (quinta-feira), às 14h, teremos a 39ª Reunião dos Gerentes de Dados da SBTMO.
Para participar, acesse no horário de início da atividade o link zoom:
us06web.zoom.us/j/8920245294…
ID da reunião: 892 0245 2945
Senha de acesso: gdsbtmo
Jayr Schmidt Filho retweeted
TRANSCEND #CLL 004
Of 137 leukapher 117->lisocel
53 (DL1=4; DL2=49) in primary efficacy ax (PAS)
median 5 lines
All BTKi exp
CR/CRi in PAS 18% ORR 43% uMRD PB 63%
mDOR 35m
PFS 12m
Responders->✅DOR
CRS 85% G3 8.5%
NE 45% G3 18%
Effective in v high risk but notable tox
#ASCO2023
